BEIJING (Reuters) – China has approved imports of Johnson & Johnson’s Tremfya (guselkumab), the National Medical Products Administration said in a notice on Friday.

The drug will be used to treat moderate to severe plaque psoriasis in adults who are suitable for systemic therapy, the administration said.

J&J is positioning Tremfya as a better alternative to Novartis’s Cosentyx as it seeks to take market share away from the treatment, which was launched two years ago and is among the top-selling treatments in the $11 billion global psoriasis market.

 

Reporting by Roxanne Liu in Beijing and Brenda Goh in Shanghai; Editing by Muralikumar Anantharaman

 

Reuters source:

https://www.reuters.com/article/us-johnson-johnson-china-tremfya/china-regulator-approves-imports-of-jjs-tremfya-idUSKBN1YV0HT